Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2005050219) QUICK TEST FOR THE DIAGNOSIS OF ALZHEIMER' DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2005/050219 International Application No.: PCT/EP2004/010889
Publication Date: 02.06.2005 International Filing Date: 29.09.2004
IPC:
C12Q 1/02 (2006.01) ,G01N 33/53 (2006.01) ,G01N 33/68 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
02
involving viable micro-organisms
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
Applicants:
ARENDT, Thomas [DE/DE]; DE (UsOnly)
STIELER, Jens [DE/DE]; DE (UsOnly)
UNIVERSITÄT LEIZIG [DE/DE]; Ritterstrasse 26 04109 Leipzip, DE (AllExceptUS)
Inventors:
ARENDT, Thomas; DE
STIELER, Jens; DE
Agent:
SCHÜSSLER, Andrea; Huber & Schüssler Truderinger Strasse 246 81252 München, DE
Priority Data:
103 49 162.722.10.2003DE
Title (EN) QUICK TEST FOR THE DIAGNOSIS OF ALZHEIMER' DISEASE
(FR) TEST RAPIDE PERMETTANT DE DIAGNOSTIQUER LA MALADIE D'ALZHEIMER
(DE) SCHNELLTEST ZUR DIAGNOSE DER ALZHEIMERSCHEN ERKRANKUNG
Abstract:
(EN) The invention relates to method for the diagnosis of Alzheimer's disease or the early stages thereof or a predisposition to said disease. Said method is based on quantitative determination of a mitogenically expressible surface marker, in particular CD69, and peripherally accessible cells, e.g. skin cells or lymphocytes, (a) prior to and (b) after mitogenic stimulation. A specific stimulation index a:b is an indication of Alzheimer's disease or early stages thereof or of a predisposition to said disease. The invention also relates to kits which are suitable for carrying out the inventive method of diagnosis.
(FR) L'invention concerne un procédé permettant de diagnostiquer la maladie d'Alzheimer, un stade précoce de cette maladie ou une prédisposition à cette maladie. Ce procédé comporte la détermination quantitative de marqueurs de surface exprimables par voie mitogène, de préférence de CD69, de cellules d'accès périphérique, par exemple, de cellules cutanées ou de lymphocytes (a) avant et (b) après une stimulation mitogène. Un certain indice de stimulation a:b est un signe de la maladie d'Alzheimer, d'un stade précoce de cette maladie ou d'une prédisposition à cette maladie. L'invention concerne également des trousses permettant de mettre en oeuvre ce procédé de diagnostic.
(DE) Beschrieben wird ein Verfahren zur Diagnose der Alzheimerschen Erkrankung oder eines Frühstadiums oder einer Prädisposition für diese Erkrankung, das auf der quantitativen Bestimmung mi­togen exprimierbarer Oberflächenmarker, vorzugsweise CD69, pe­ripher zugänglicher Zellen, z.B. Hautzellen oder Lymphozyten, (a) vor und (b) nach mitogener Stimulation erfolgt, wobei ein bestimmter Stimulationsindex a:b ein Anzeichen für Alzheimer­sche Erkrankung oder ein Frühstadium oder eine Prädisposition für diese Erkrankung ist. Schließlich werden auch Kits be­schrieben, die zur Durchführung des erfindungsgemäßen Diagno­severfahrens geeignet sind.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: German (DE)
Filing Language: German (DE)